Your browser doesn't support javascript.
loading
Are we ready to use anti-amyloid therapy in Alzheimer's disease?
Brucki, Sonia Maria Dozzi; César-Freitas, Karolina Gouveia; Spera, Raphael Ribeiro; Borges, Conrado Regis; Smid, Jerusa.
Afiliación
  • Brucki SMD; Universidade de São Paulo, Departamento de Neurologia, Unidade de Neurologia Cognitiva e Comportamental, São Paulo SP, Brazil.
  • César-Freitas KG; Universidade de São Paulo, Departamento de Neurologia, Unidade de Neurologia Cognitiva e Comportamental, São Paulo SP, Brazil.
  • Spera RR; Universidade de São Paulo, Departamento de Neurologia, Unidade de Neurologia Cognitiva e Comportamental, São Paulo SP, Brazil.
  • Borges CR; Universidade de São Paulo, Departamento de Neurologia, Unidade de Neurologia Cognitiva e Comportamental, São Paulo SP, Brazil.
  • Smid J; Universidade de São Paulo, Departamento de Neurologia, Unidade de Neurologia Cognitiva e Comportamental, São Paulo SP, Brazil.
Arq Neuropsiquiatr ; 80(5 Suppl 1): 15-23, 2022 05.
Article en En | MEDLINE | ID: mdl-35976307
Alzheimer's disease (AD) is the most common neurodegenerative disease. Biomarkers have demonstrated that AD pathology exists over the disease continuum from a stage preceding symptoms over 15-25 years to the progressively more impaired symptomatic states, mild cognitive impairment (MCI), and dementia. Biomarkers include: amyloid (Aß), phosphorylated tau, and neurodegeneration. The plasma assays for Aß and tau show great promise for clinical and research use. This review has aimed not only to present the ATN diagnostic classification and the preclinical AD concepts in addressing some possibilities of cognitive assessment instruments, but also to briefly summarize the main anti-amyloid monoclonal antibodies studied in clinical trials. In addition, this paper presents a critical analysis by experts in cognitive neurology while addressing the question as to whether we are prepared for the anti-amyloid therapy era or not.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Neurodegenerativas / Enfermedad de Alzheimer / Disfunción Cognitiva Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: Arq Neuropsiquiatr Año: 2022 Tipo del documento: Article País de afiliación: Brasil Pais de publicación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Neurodegenerativas / Enfermedad de Alzheimer / Disfunción Cognitiva Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: Arq Neuropsiquiatr Año: 2022 Tipo del documento: Article País de afiliación: Brasil Pais de publicación: Alemania